<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891991</url>
  </required_header>
  <id_info>
    <org_study_id>CU272021</org_study_id>
    <nct_id>NCT04891991</nct_id>
  </id_info>
  <brief_title>Intravitreal Infliximab for Proliferative Vitreoretinopathy</brief_title>
  <acronym>FIXER</acronym>
  <official_title>Treatment of Proliferative Vitreoretinopathy With Intravitreal Infliximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous&#xD;
      retinal detachment repair and is characterized by the growth and contraction of cellular&#xD;
      membranes within the vitreous cavity on both sides of the retinal surface as well as&#xD;
      intraretinal fibrosis.&#xD;
&#xD;
      Multiple therapeutic agents have been tried as an adjunctive to retinal detachment surgery&#xD;
      for PVR with no consistent efficacy. Tumor necrosis factor-α (TNF-α), which is a prominent&#xD;
      inflammatory cytokine, is secreted in response to trauma, infection, and inflammation. It is&#xD;
      a key mediator of ocular inflammation and its interactions with the retinal pigment&#xD;
      epithelium (RPE) cell contribute to the initiation of PVR. This may occur through the action&#xD;
      of TNF-α on the RPE cells inducing changes in cellular morphologies that lead to the&#xD;
      formation of fibroblastic cells.&#xD;
&#xD;
      Infliximab (Remicade; Janssen Biotech, Horsham, PA, USA) is a mouse-human chimeric antibody&#xD;
      that neutralizes the biological activity of TNF-α by high-affinity binding to the soluble and&#xD;
      transmembrane forms of TNF-α, therefore preventing the effective binding of TNF-α with its&#xD;
      receptors. Infliximab is used in the treatment of various ocular and systemic inflammatory&#xD;
      conditions. Furthermore, intravitreal infliximab has been used for the treatment of various&#xD;
      ocular diseases and has proven to be generally safe for the short term in inflammatory ocular&#xD;
      conditions. A recent study showed that intravitreal infliximab can inhibit the development of&#xD;
      PVR and reduce levels of cytokines in an experimental dispase-induced PVR model.&#xD;
&#xD;
      The purpose of this randomized controlled trial is to evaluate the efficacy of intravitreal&#xD;
      infliximab injection as an adjunct to pars plana vitrectomy in the treatment of PVR&#xD;
      associated with primary rhegmatogenous retinal detachment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous&#xD;
      retinal detachment repair and is characterized by the growth and contraction of cellular&#xD;
      membranes within the vitreous cavity on both sides of the retinal surface as well as&#xD;
      intraretinal fibrosis.&#xD;
&#xD;
      The incidence of PVR in all cases of retinal detachment is estimated to be 5- 10%. The&#xD;
      incidence of PVR has largely remained unchanged in prospective studies despite the evolution&#xD;
      of vitreoretinal techniques over the past 25 years, including valved trocars and smaller&#xD;
      gauge instrumentation.&#xD;
&#xD;
      Numerous risk factors for the development of PVR have been identified. Almost all risk&#xD;
      factors for PVR are associated with intravitreal dispersion of retinal pigment epithelial&#xD;
      cells or breakdown of the blood-ocular barrier. Following a retinal break, the retinal&#xD;
      pigment epithelial (RPE) cells are exposed to the vitreous cavity to react to growth factors&#xD;
      and cytokines in the vitreous, resulting in a forward feedback to secret more growth factors&#xD;
      and cytokines to further stimulate cellular responses.&#xD;
&#xD;
      Multiple therapeutic agents have been tried as an adjunctive to retinal detachment surgery&#xD;
      for PVR with no consistent efficacy. Tumor necrosis factor-α (TNF-α), which is a prominent&#xD;
      inflammatory cytokine, is secreted in response to trauma, infection, and inflammation. It is&#xD;
      a key mediator of ocular inflammation and its interactions with RPE cells contribute to the&#xD;
      initiation of PVR. This is because TNF-α was found to act on the RPE cells consequently&#xD;
      inducing changes in cellular morphologies leading to the formation of fibroblastic cells.&#xD;
      Additionally, if TNF-α is combined with other growth factors, a strong synergistic effect can&#xD;
      be induced to form epithelial-mesenchymal transition (EMT)-associated fibrotic focus.&#xD;
&#xD;
      Infliximab (Remicade; Janssen Biotech, Horsham, PA, USA) is a mouse-human chimeric antibody&#xD;
      that neutralizes the biological activity of TNF-α by high-affinity binding to the soluble and&#xD;
      transmembrane forms of TNF-α, therefore preventing the effective binding of TNF-α with its&#xD;
      receptors. Infliximab is used in the treatment of various ocular and systemic inflammatory&#xD;
      conditions. Furthermore, intravitreal infliximab has been used for the treatment of various&#xD;
      ocular diseases and has proven to be generally safe for the short term in inflammatory ocular&#xD;
      conditions. A recent study showed that intravitreal infliximab can inhibit the development of&#xD;
      PVR and reduce levels of cytokines in an experimental dispase-induced PVR model.&#xD;
&#xD;
      The purpose of this randomized controlled trial is to evaluate the efficacy of intravitreal&#xD;
      infliximab injection as an adjunct to pars plana vitrectomy in the treatment of PVR&#xD;
      associated with primary rhegmatogenous retinal detachment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2021</start_date>
  <completion_date type="Anticipated">November 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anatomical success</measure>
    <time_frame>9 months</time_frame>
    <description>Anatomical Success will be defined as stable complete retinal reattachment following pars plana vitrectomy and silicone oil removal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1, 3, 6, and 9 months</time_frame>
    <description>Best corrected visual acuity will be measured at follow up visits using standard Snellen charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular structure</measure>
    <time_frame>1, 3, 6, and 9 months</time_frame>
    <description>Optical coherence tomography will be done at each follow up visit to assess the structure of the macula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular vascularity</measure>
    <time_frame>7 months</time_frame>
    <description>Optical coherence tomography angiography will be done at each follow up visit to assess macular vascular density.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular function</measure>
    <time_frame>7 months</time_frame>
    <description>Macular function will be assessed during follow up visits using multifocal electroretinography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single operation success rate</measure>
    <time_frame>9 months</time_frame>
    <description>The rate of successful retinal reattachment following a single operation will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>9 months</time_frame>
    <description>Cumulative rate of recurrence of retinal detachment and reoperation following the primary surgery will be calculated during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epiretinal proliferative</measure>
    <time_frame>1, 3, 6, and 9 months</time_frame>
    <description>The formation of significant epiretinal proliferation will be assessed clinically at each follow up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Rhegmatogenous Retinal Detachment</condition>
  <condition>Proliferative Vitreoretinopathy</condition>
  <condition>Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>Infliximab group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive 1 mg/0.05 mL of intravitreal infliximab at the end of standard pars plana vitrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will undergo standard pars plana vitrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal infliximab</intervention_name>
    <description>1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.</description>
    <arm_group_label>Infliximab group</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy</intervention_name>
    <description>Standard pars plana vitrectomy</description>
    <arm_group_label>Infliximab group</arm_group_label>
    <arm_group_label>Standard of care group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: more than or equal to 18 years&#xD;
&#xD;
          -  Primary rhegmatogenous retinal detachment with proliferative vitreoretinopathy more&#xD;
             than or equal to grade C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of open globe injury&#xD;
&#xD;
          -  Recurrent retinal detachment or primary failed retinal detachment surgery&#xD;
&#xD;
          -  History of vitreoretinal procedure&#xD;
&#xD;
          -  Retinal vascular diseases (Diabetic retinopathy, retinal vein occlusion,...etc)&#xD;
&#xD;
          -  Pregnant or breastfeeding females&#xD;
&#xD;
          -  Inability to attend regular follow-up visits&#xD;
&#xD;
          -  History of pulmonary or extra-pulmonary tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman G Elnahry, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hany S Hamza, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M Younes, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed A Abdel-Kader, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M Abdelbaki, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman G Elnahry, MD, PhD</last_name>
    <phone>+201224927604</phone>
    <email>ayman_elnahri@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed M Younes, MD, MSc</last_name>
    <phone>+201098911384</phone>
    <email>ahmedyounes16791@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998 Jan;17(1):77-98. Review.</citation>
    <PMID>9537796</PMID>
  </reference>
  <reference>
    <citation>Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998 Jul-Aug;43(1):3-18. Review.</citation>
    <PMID>9716190</PMID>
  </reference>
  <reference>
    <citation>Pastor JC, de la Rúa ER, Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002 Jan;21(1):127-44. Review.</citation>
    <PMID>11906814</PMID>
  </reference>
  <reference>
    <citation>Pennock S, Haddock LJ, Mukai S, Kazlauskas A. Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy. Am J Pathol. 2014 Nov;184(11):3052-68. doi: 10.1016/j.ajpath.2014.07.026. Epub 2014 Sep 26.</citation>
    <PMID>25261788</PMID>
  </reference>
  <reference>
    <citation>Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond). 2002 Jul;16(4):369-74. Review.</citation>
    <PMID>12101443</PMID>
  </reference>
  <reference>
    <citation>Leiderman YI, Miller JW. Proliferative vitreoretinopathy: pathobiology and therapeutic targets. Semin Ophthalmol. 2009 Mar-Apr;24(2):62-9. doi: 10.1080/08820530902800082. Review.</citation>
    <PMID>19373688</PMID>
  </reference>
  <reference>
    <citation>Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, Hilgers RD, Foerster MH; Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment Study Group. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. Ophthalmology. 2007 Dec;114(12):2142-54.</citation>
    <PMID>18054633</PMID>
  </reference>
  <reference>
    <citation>Savur F, Aydemir O, İlhan N. The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy. Cutan Ocul Toxicol. 2020 Mar;39(1):61-66. doi: 10.1080/15569527.2019.1701000. Epub 2019 Dec 17.</citation>
    <PMID>31809602</PMID>
  </reference>
  <reference>
    <citation>Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012 Sep;154(3):534-541.e1. doi: 10.1016/j.ajo.2012.03.035. Epub 2012 Jul 11.</citation>
    <PMID>22789563</PMID>
  </reference>
  <reference>
    <citation>Pascual-Camps I, Hernández-Martínez P, Monje-Fernández L, Dolz-Marco R, Gallego-Pinazo R, Wu L, Arévalo JF, Díaz-Llopis M. Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders. J Ophthalmic Inflamm Infect. 2014 Oct 15;4:26. doi: 10.1186/s12348-014-0026-8. eCollection 2014. Review.</citation>
    <PMID>25825604</PMID>
  </reference>
  <reference>
    <citation>Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016 Mar;51:125-55. doi: 10.1016/j.preteyeres.2015.07.005. Epub 2015 Jul 21. Review.</citation>
    <PMID>26209346</PMID>
  </reference>
  <reference>
    <citation>Hamza MM, Macky TA, Sidky MK, Ragab G, Soliman MM. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study. Retina. 2016 Dec;36(12):2399-2408.</citation>
    <PMID>27870802</PMID>
  </reference>
  <reference>
    <citation>Korthagen NM, van Bilsen K, Swagemakers SM, van de Peppel J, Bastiaans J, van der Spek PJ, van Hagen PM, Dik WA. Retinal pigment epithelial cells display specific transcriptional responses upon TNF-α stimulation. Br J Ophthalmol. 2015 May;99(5):700-4. doi: 10.1136/bjophthalmol-2014-306309. Epub 2015 Feb 13.</citation>
    <PMID>25680620</PMID>
  </reference>
  <reference>
    <citation>Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res. 2014 May;40:16-34. doi: 10.1016/j.preteyeres.2013.12.006. Epub 2014 Jan 9. Review.</citation>
    <PMID>24412519</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ayman Gehad Elnahry</investigator_full_name>
    <investigator_title>Lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

